Tag: neurology

Up to 76% of People With Alzheimer’s Disease Experience Agitation. The First Non-Antipsychotic Drug Approved for It Just Arrived.

The essentials: On April 30, 2026, the FDA approved Auvelity (dextromethorphan HBr and bupropion HCl, Axsome Therapeutics) for the treatment of agitation associated with dementia due to Alzheimer’s disease in adults. This is the first FDA-approved treatment for Alzheimer’s disease agitation that is not an antipsychotic, and only the second FDA-approved drug for this indication overall. Auvelity’s first approved indication was major depressive disorder in adults (August 2022). The mechanism: dextromethorphan is an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist; bupropion serves as a CYP2D6 inhibitor that slows dextromethorphan metabolism, substantially increasing dextromethorphan blood levels. Auvelity is a first-in-class treatment combining NMDA antagonism and sigma-1 modulation for agitation in Alzheimer’s disease. Regulatory designation: Breakthrough Therapy Designation (2020). The clinical basis: Phase 3 ADVANCE-1 trial (NCT03226522, 5-week parallel-group RCT, n=308) and Phase 3 ACCORD-2 randomized withdrawal trial (NCT04947553, 26-week randomized withdrawal among responders). ADVANCE-1 primary endpoint: statistically significant reduction in Cohen-Mansfield Agitation Inventory (CMAI) total score at week 5 versus placebo. ACCORD-2 primary endpoint: significantly longer time to relapse (HR 0.276; p=0.001) and lower relapse incidence (8.4% vs. 28.6%) in those continuing Auvelity versus switched to placebo. Important nuance: ADVANCE-2, a second 5-week parallel-group trial (n=408), missed its CMAI primary endpoint, though secondary measures showed numerical improvements. Boxed warning: increased risk of suicidal thoughts and behaviors (antidepressant class warning). Serious risks in elderly patients: seizures, elevated blood pressure, mania. Dosing: one tablet (45 mg dextromethorphan / 105 mg bupropion) twice daily.

Agitation in Alzheimer’s disease is one of the most distressing and difficult-to-manage aspects of the condition, for patients and for caregivers alike. It is not simply behavioral inconvenience. It encompasses excessive motor activity, verbal aggression, physical aggression, emotional distress, disinhibition, and disruptive irritability. It occurs in an estimated 40 to 76% of people with Alzheimer’s disease over the course of their illness. It is among the leading drivers of nursing home placement. It contributes to caregiver burnout. And until April 30, 2026, the only FDA-approved drug for it was brexpiprazole (Rexulti), an atypical antipsychotic that carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis.

That warning, applied class-wide to all antipsychotics in this population, has made prescribers appropriately cautious. Antipsychotics are associated with increased risk of death in elderly dementia patients, an association serious enough to generate the FDA’s black box in 2005 for typical antipsychotics and 2008 for atypical antipsychotics. They have nonetheless been widely used off-label for Alzheimer’s agitation because the need was so severe and the alternatives so limited.

On April 30, 2026, the FDA approved the first non-antipsychotic option. Auvelity (dextromethorphan-bupropion) targets NMDA receptors and sigma-1 receptors through a mechanism entirely distinct from dopamine receptor blockade, providing a pharmacological approach that does not carry the mortality warning applied to antipsychotics in this population.

The clinical data behind the approval requires honest presentation: it is more nuanced than the headline suggests, and families and clinicians deserve a complete picture.

What Alzheimer’s Disease Agitation Is and Why It Is So Hard to Treat

Defining agitation in the context of dementia

Agitation in Alzheimer’s disease is formally defined as behavior that includes at least one of three domains: excessive motor activity (pacing, handwringing, rocking); verbal aggression (screaming, cursing, threatening); or physical aggression (hitting, biting, scratching). To meet a clinical threshold for treatment, these behaviors must be associated with distress in the patient, represent a change from premorbid behavior, and not be solely attributable to another medical cause or psychosis.

The Cohen-Mansfield Agitation Inventory (CMAI), the instrument used as the primary efficacy measure in ADVANCE-1, is a validated 29-item scale assessing the frequency of specific agitated behaviors on a scale from 1 (never) to 7 (several times per hour). Higher scores indicate more frequent agitation. The CMAI is the most widely used and well-validated agitation measure in Alzheimer’s disease research and has been accepted by the FDA as a primary endpoint in this indication.

The pathophysiology behind agitation in Alzheimer’s disease

Agitation in Alzheimer’s disease is not simply a behavioral response to cognitive decline. It reflects specific neurobiological changes in the Alzheimer’s brain: degeneration of the prefrontal cortex and its connections impairs impulse control and emotional regulation; locus coeruleus neurodegeneration disrupts norepinephrine signaling affecting arousal and stress responses; and aberrant glutamate signaling through NMDA receptors contributes to the excitotoxic and dysregulated neuronal activity associated with agitation and other behavioral symptoms.

This neurobiological basis for agitation is what makes the NMDA antagonist mechanism of dextromethorphan a rational pharmacological target, distinct from the dopamine-based mechanism of antipsychotics.

Why off-label antipsychotics have remained standard despite the mortality risk The FDA issued boxed warnings for both typical and atypical antipsychotics in dementia patients between 2005 and 2008, following multiple trials and pharmacovigilance analyses showing a 1.6 to 1.7-fold increased risk of death versus placebo in elderly patients with dementia-related psychosis and behavioral disturbances. Despite this warning, antipsychotics (particularly quetiapine, risperidone, and haloperidol) have continued to be widely prescribed for Alzheimer’s agitation off-label, because the severity of unmanaged agitation creates a real and urgent clinical need that outweighs the mortality risk for many patients in institutional settings. The lack of an approved non-antipsychotic alternative for more than 15 years is the direct reason for this uncomfortable clinical reality. The approval of brexpiprazole in 2023 addressed the first part of the gap: an FDA-approved indication for Alzheimer agitation. But it is still an antipsychotic carrying the same mortality warning. Auvelity addresses the second part: a genuinely mechanistically distinct option without that class-level mortality warning.

How Auvelity Works in Alzheimer’s Disease Agitation

Auvelity’s pharmacology in Alzheimer’s disease agitation reflects the same mechanism that supported its 2022 approval for major depressive disorder, applied to a different behavioral target.

Dextromethorphan: the pharmacologically active agent

Dextromethorphan (DXM) is a synthetic morphinan compound familiar as the cough-suppressing active ingredient in many over-the-counter cold preparations. At the doses used in Auvelity, which are substantially higher than OTC cough suppressant doses, it acts as an uncompetitive NMDA receptor antagonist and a sigma-1 receptor agonist.

NMDA receptor antagonism: NMDA receptors are glutamate receptors involved in synaptic plasticity, learning, and memory but also in excitotoxic signaling when overactivated. In Alzheimer’s disease, aberrant NMDA receptor activity is implicated in both neurodegeneration and behavioral dysregulation. Blocking these receptors, as memantine (Namenda) does (memantine is an FDA-approved NMDA antagonist for moderate to severe Alzheimer’s cognitive symptoms), may reduce the neurochemical substrate for agitation. DXM’s NMDA antagonism is uncompetitive, meaning it binds the receptor channel in its open state, providing a rapid blocking effect that differs pharmacodynamically from memantine’s competitive inhibition.

Sigma-1 receptor agonism: The sigma-1 receptor is a chaperone protein in the endoplasmic reticulum of neurons involved in neuroplasticity, neuroprotection, and neurotransmitter regulation. Sigma-1 agonism may have independent anxiolytic and neuroprotective effects relevant to Alzheimer’s disease behavioral symptoms.

Bupropion: the pharmacokinetic enabler

Bupropion is an aminoketone antidepressant that inhibits CYP2D6, the hepatic enzyme responsible for metabolizing dextromethorphan. When taken alone, DXM is rapidly metabolized by CYP2D6 and does not achieve sustained therapeutic blood levels for neuropsychiatric indications. Bupropion’s CYP2D6 inhibition blocks this metabolism, dramatically increasing DXM blood levels and duration of action, achieving therapeutic NMDA and sigma-1 receptor engagement that OTC doses of DXM cannot.

This pharmacokinetic partnership is the core mechanism behind Auvelity’s design: bupropion is not chosen for its antidepressant properties in this combination (the bupropion-alone arm in ADVANCE-1 was terminated for futility, confirming bupropion alone has no meaningful effect on Alzheimer’s agitation) but because it makes DXM pharmacologically effective at lower doses with better tolerability.

The Clinical Evidence: Two Trials, a Complete Picture

The FDA’s approval is based on two Phase 3 trials: ADVANCE-1 (positive) and ACCORD-2 (positive). A third trial, ADVANCE-2, also informed the totality of evidence but missed its primary endpoint and deserves honest presentation.

ADVANCE-1 (NCT03226522): the 5-week parallel-group primary efficacy trial

ADVANCE-1 was a randomized, double-blind, 5-week, parallel-group, placebo-controlled Phase 3 trial in adults with Alzheimer’s disease and moderate to severe agitation. The trial enrolled 308 patients across three arms: Auvelity (n=152), placebo (n=156), and bupropion alone (n, terminated early for futility).

Primary endpoint: Change in CMAI total score from baseline at week 5.

Auvelity versus placebo (CMAI change): Auvelity was statistically significantly superior to placebo in reducing CMAI total score at week 5. The improvement was consistent with clinically meaningful agitation reduction.

Key secondary endpoint: A statistically significantly greater proportion of Auvelity-treated patients were rated by clinicians as “minimally improved” or better on the modified Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change (mADCS-CGIC) at week 5.

Bupropion-alone arm: Terminated for futility at a planned interim analysis, confirming that bupropion alone has no clinically meaningful effect on Alzheimer’s agitation. This is an important finding: it confirms that the efficacy of Auvelity is attributable to the pharmacological effect of enhanced DXM rather than to bupropion’s antidepressant or dopaminergic properties.

ACCORD-2 (NCT04947553): the 26-week randomized withdrawal durability trial

ACCORD-2 used a different trial design: an open-label lead-in phase in which all patients received Auvelity, followed by randomization (only among responders who achieved sustained response) to continue Auvelity or switch to placebo for up to 26 weeks. This enriched randomized withdrawal design is appropriate for evaluating whether response is maintained over longer treatment periods.

Open-label lead-in findings: Patients showed rapid CMAI improvement during the lead-in phase, with a mean reduction of 20.4 points at week 6 (46% reduction from baseline). Approximately 69% achieved at least a 30% response, qualifying them for the randomized withdrawal phase.

Randomized withdrawal phase primary endpoint: Time to relapse of agitation symptoms.

Outcome	Continue Auvelity	Switch to placebo
Hazard ratio for relapse	0.276	Reference
p-value	0.001	—
Relapse incidence	8.4%	28.6%

Patients continuing Auvelity experienced significantly longer time to relapse and substantially lower relapse incidence than those switched to placebo. The approximately 72% reduction in relative relapse risk over 26 weeks confirms durable maintenance of the anti-agitation response.

The important design caveat: Because ACCORD-2 enrolled only patients who had responded to Auvelity before randomization, its relapse findings should be interpreted in the context of an enriched responder population. It confirms that Auvelity works in those who respond; it cannot speak to what proportion of all Alzheimer’s agitation patients will respond.

ADVANCE-2: the missed primary endpoint, presented honestly

ADVANCE-2 was a second 5-week parallel-group trial in 408 participants with Alzheimer’s agitation. Unlike ADVANCE-1, it missed its primary endpoint: the between-group difference in CMAI change at week 5 was −13.8 in the Auvelity arm versus −12.6 in the placebo arm, not reaching statistical significance. Secondary measures showed numerical improvements but these were not formally significant given the failed primary endpoint.

The FDA’s approval despite ADVANCE-2’s failure reflects the totality of evidence approach: ADVANCE-1 met its primary endpoint, ACCORD-2 met its primary endpoint with a compelling relapse reduction effect, the bupropion-futility finding provides mechanistic clarity, and the long-term safety data is favorable. The difference between ADVANCE-1 and ADVANCE-2 results in the same endpoint is not fully explained and represents genuine clinical uncertainty about the magnitude of benefit in all patients.

This is important information for families and clinicians: Auvelity works meaningfully for many patients, but the clinical evidence includes one failed parallel-group trial, and not every patient should be expected to respond.

Auvelity’s Second Indication: How This Differs From the MDD Approval

Auvelity was first approved in August 2022 for major depressive disorder in adults, based on the GEMINI and ASCEND trials demonstrating rapid antidepressant effects. The Alzheimer’s agitation indication uses the same drug at the same dose but for a neurobiologically and clinically distinct target.

This creates some complexity for prescribers:

The boxed warning for suicidal thoughts in adolescents and young adults is a class effect from the antidepressant pharmacology of bupropion; while the approved Alzheimer’s agitation indication covers elderly adults (who are at lower background risk of this complication), the warning is still on the label
In Alzheimer’s disease patients specifically, separating depression from agitation is clinically important: depression is very common in Alzheimer’s disease, and Auvelity’s dual indication means it may be considered for patients who have both conditions, though the trials studied these separately
Drug interactions relevant to bupropion’s CYP2D6 inhibition are the same across indications

Auvelity’s Place in Alzheimer’s Disease Agitation Treatment

With this approval, two drugs now have FDA approval for Alzheimer’s disease agitation:

Drug	Company	Mechanism	Approval date	Boxed warning
Brexpiprazole (Rexulti)	Otsuka/Lundbeck	Atypical antipsychotic (partial D2 agonist)	May 2023	Increased mortality in elderly patients with dementia-related psychosis
Auvelity (dextromethorphan-bupropion)	Axsome Therapeutics	NMDA antagonist/sigma-1 agonist	April 30, 2026	Suicidal thoughts (antidepressant class); no dementia mortality warning

The absence of a dementia-specific mortality warning on Auvelity does not mean it is risk-free in this population. It means its mechanism (NMDA antagonism rather than dopamine receptor blockade) does not carry the class-level mortality association established for antipsychotics. Individual patient risk-benefit assessment by a qualified clinician familiar with the patient’s full medical picture remains essential.

For patients who are not appropriate candidates for antipsychotic therapy, including those with Parkinson’s disease or Lewy body dementia where antipsychotics carry heightened risk, Auvelity may be a particularly relevant option.

Safety: What the Prescribing Information Covers

Boxed warning

Increased risk of suicidal thoughts and behaviors: All antidepressants, including bupropion (a component of Auvelity), carry a class-level boxed warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults. The Alzheimer’s agitation indication is in elderly adults, where this risk is substantially lower, but the warning is present on the label. Monitor for clinical worsening and emergence of suicidal thoughts in all patients.

Warnings specific to elderly Alzheimer’s patients

Seizure risk: Bupropion is associated with dose-dependent seizure risk. This risk is relevant in elderly Alzheimer’s patients who may have underlying cerebrovascular disease, which independently increases seizure risk. The seizure warning in the prescribing information is particularly relevant in patients with prior seizures, CNS tumors, or concurrent medications that lower the seizure threshold.

Elevated blood pressure and hypertension: Bupropion inhibits norepinephrine reuptake, which can elevate blood pressure. Monitor blood pressure before starting and periodically during treatment. In elderly patients with cardiovascular disease, this is a clinically important consideration.

Activation of mania or hypomania: Relevant primarily for patients with undiagnosed or undertreated bipolar disorder.

Common adverse events (occurring in at least 5% and more than twice placebo in ADVANCE-1)

Dizziness, nausea, headache, diarrhea, somnolence, dry mouth, hyperhidrosis.

Drug interactions

Because bupropion is a CYP2D6 inhibitor, Auvelity will increase the plasma concentration of other CYP2D6-metabolized drugs (including many antidepressants, antipsychotics, beta-blockers, and opioids). Review the full prescribing information for the complete interaction table. This is particularly relevant in elderly patients on multiple medications.

Dosing

One extended-release tablet (dextromethorphan 45 mg / bupropion 105 mg) taken twice daily, morning and evening. Do not crush, cut, or chew the extended-release tablet. The tablet can be taken with or without food.

For Patients, Families, and Caregivers

What Auvelity is and is not

Auvelity is a treatment for agitation in Alzheimer’s disease. It is not a cognitive enhancer, does not slow disease progression, and is not a substitute for existing Alzheimer’s disease treatments such as donepezil, memantine, or lecanemab. It specifically targets one of the most disabling behavioral symptoms of Alzheimer’s disease.

What to expect if starting treatment

If Auvelity is prescribed, the ACCORD-2 open-label data showed that meaningful agitation improvement became apparent within the first several weeks of treatment, with about 69% of patients achieving at least a 30% improvement by week 6. Not all patients will respond. If no meaningful improvement is seen after an adequate trial, this should prompt discussion with the prescribing clinician about alternative management strategies.

Caregiver considerations

Alzheimer’s disease agitation is one of the most significant drivers of caregiver distress and burnout. The availability of a non-antipsychotic FDA-approved option may facilitate earlier treatment consideration in patients where clinicians or families have been reluctant to start antipsychotic therapy.

The Alzheimer’s Association maintains current resources on managing behavioral symptoms in Alzheimer’s disease, including agitation, with clinical guidance for families navigating these decisions. The Family Caregiver Alliance provides practical support resources specifically for dementia caregivers. The National Institute on Aging maintains current information on all FDA-approved Alzheimer’s treatments.

For related HED coverage on Alzheimer’s disease treatment advances and FDA approvals, see our post on AVLAYAH, the first gene therapy crossing the blood-brain barrier to reach neurons in Hunter syndrome for context on how the BBB problem in neurological disease is being approached across conditions, and our post on Ocrevus expanding to pediatric multiple sclerosis as another example of 2026 approvals expanding the treatment toolkit for neurological conditions.

Sources

FDA press announcement: FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia. FDA.gov. April 30, 2026.

Axsome Therapeutics press release: Axsome Therapeutics Announces FDA Approval of Auvelity (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease. GlobeNewswire. April 30, 2026.

Drugs.com approval news: Axsome Therapeutics Announces FDA Approval of Auvelity for Agitation Associated with Dementia. drugs.com. April 30, 2026.

Psychiatric Times detailed clinical summary: FDA Approves Auvelity for Treatment of Agitation in Alzheimer Disease. psychiatrictimes.com. May 2026.

NeurologyLive detailed coverage: FDA Approves AXS-05 as New Treatment for Alzheimer Disease Agitation. neurologylive.com. May 2026.

Neurology Advisor: Auvelity Gains Approval for Agitation in Alzheimer Disease. neurologyadvisor.com. April 2026.

Conexiant clinical summary: FDA Approves Auvelity for Agitation in Alzheimer’s Disease. conexiant.com. April 2026.

AJMC: FDA Approves Dextromethorphan-Bupropion for Agitation Due to Alzheimer Disease. ajmc.com. May 2026.

Pharmacy Times: FDA Approves First Non-Antipsychotic Treatment for Agitation Associated with Alzheimer Disease. pharmacytimes.com. 2026.

Consultant360: FDA Approves Auvelity for Agitation in Alzheimer Disease Dementia. consultant360.com. May 2026.

ADVANCE-1 trial registration: NCT03226522. ClinicalTrials.gov.

ACCORD-2 trial registration: NCT04947553. ClinicalTrials.gov.

Brexpiprazole Alzheimer agitation FDA approval: FDA approves brexpiprazole for agitation associated with Alzheimer’s disease dementia. FDA.gov. May 2023.

Auvelity prescribing information: Auvelity (dextromethorphan HBr and bupropion HCl) Prescribing Information. Axsome Therapeutics. 2026.

Alzheimer’s disease agitation overview: Neuropsychiatric Symptoms in Alzheimer’s Disease. PMC8461428.

CMAI instrument: Cohen-Mansfield Agitation Inventory. PMC5880688.

NMDA receptor antagonism in AD: NMDA Receptor Antagonists in Alzheimer’s Disease. PMC5542145.

Sigma-1 receptor: Sigma-1 Receptor in Neurological Disorders. PMC6370317.

Dextromethorphan pharmacology: Dextromethorphan. StatPearls. NCBI.

Bupropion: Bupropion. StatPearls. NCBI.

CYP2D6: CYP2D6. StatPearls. NCBI.

Memantine FDA approval: FDA approves memantine for moderate to severe Alzheimer’s disease. FDA.gov.

Agitation StatPearls: Agitation and Delirium in Elderly. StatPearls. NCBI.

Patient resources: Alzheimer’s Association: Behavioral Symptoms | Family Caregiver Alliance | National Institute on Aging: Alzheimer’s Treatments

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Auvelity carries a boxed warning for suicidal thoughts and behaviors associated with antidepressant medications. Decisions about treatment for Alzheimer’s disease agitation, including whether Auvelity is appropriate for a specific patient, should be made in close consultation with a qualified neurologist, geriatric psychiatrist, or geriatrician familiar with the patient’s complete medical history, current medications, and clinical circumstances.

June 7, 2026

The Only Approved High-Efficacy MS Treatment for Children Is Now Ocrevus. Here Is What the OPERETTA 2 Trial Data Shows.

📌 The essentials On May 8, 2026, the FDA approved Ocrevus (ocrelizumab, Genentech) for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10 years and older who weigh at least 25 kg (approximately 55 pounds). This is Ocrevus’s first pediatric indication, expanding its label beyond adults. Ocrevus becomes only the second FDA-approved disease-modifying therapy for pediatric RRMS, after fingolimod (Gilenya, Novartis), and the first approved high-efficacy anti-CD20 therapy for this population. The clinical basis: Phase 3 OPERETTA 2 trial (NCT05123703), 187 pediatric patients aged 10 to 17 years with RRMS, randomized double-blind comparison of ocrelizumab versus fingolimod. Primary endpoint: ocrelizumab was non-inferior to fingolimod in reducing annualized relapse rate. MRI superiority: 48% reduction in new or enlarging T2 lesions (p=0.001) and 87% reduction in gadolinium-enhancing T1 lesions (p=0.001) versus fingolimod. Safety: no adverse events led to treatment withdrawal in the ocrelizumab arm. How it is given: 600 mg intravenous infusion every 24 weeks (same dose and schedule as adults). Weight minimum: the drug is not known to be safe or effective in children under 10 years of age or weighing less than 25 kg.

Multiple sclerosis in children and adolescents is a different clinical scenario than most people picture when they think of MS. Pediatric-onset MS (POMS) represents approximately 3 to 5% of all MS cases globally, with an estimated 5,000 to 10,000 children and adolescents affected in the United States. The condition is not mild: children with POMS typically have higher relapse rates than adults, more rapid accumulation of new brain lesions on MRI, and a relapsing disease course in the vast majority of cases. What they have historically had is very few approved treatment options.

Until May 8, 2026, fingolimod (Gilenya) was the only FDA-approved disease-modifying therapy for pediatric RRMS, a status it has held since its pediatric approval in 2018. Every other MS treatment used in children and adolescents was prescribed off-label, without the clinical trial evidence base that formal approval requires.

That changed when the FDA approved Ocrevus (ocrelizumab) for RRMS in patients aged 10 and older, based on the Phase 3 OPERETTA 2 trial. For the first time, a high-efficacy anti-CD20 B-cell depleting therapy is formally available for pediatric patients who have not responded adequately to first-line agents or whose disease activity warrants a more aggressive approach from the start.

What Pediatric-Onset Multiple Sclerosis Is and Why Treatment Is Urgent

Pediatric-onset MS is defined as MS with symptom onset before age 18. Children and adolescents with POMS experience the same types of episodes as adults, including optic neuritis, limb weakness, sensory disturbance, brainstem and cerebellar dysfunction, and cognitive slowing. But several features distinguish POMS from typical adult-onset disease.

Higher initial disease activity: Children with POMS typically have higher relapse rates than adult patients early in the disease course. Brain MRI at diagnosis often shows extensive T2 lesion burden. The inflammatory activity is often vigorous, reflecting the heightened immune responsiveness of the developing immune system.

Predominantly relapsing course: Nearly all pediatric MS cases are relapsing-remitting, not progressive, at onset. This is both a prognostic advantage (the disease course is more amenable to disease modification) and a treatment priority (relapses in developing brains carry distinct risks for cognitive and neurological development that are not fully quantified in adults).

Cognitive burden: Cognitive impairment is documented in a substantial proportion of children with MS, affecting processing speed, attention, memory, and executive function. Because POMS occurs during a critical period of brain development and education, the impact of unchecked disease activity on long-term cognitive trajectory is a distinct and serious concern.

Long disease duration ahead: A child diagnosed at age 12 faces potentially decades of living with MS before the disease is biologically comparable to someone diagnosed at 50. The cumulative burden of every avoided relapse, every suppressed lesion, and every year of preserved neurological function compounds over that longer horizon.

Why fingolimod was the only approved option for so long, and what its limitations are Fingolimod (Gilenya) was the first FDA-approved MS therapy for pediatric patients, receiving its pediatric RRMS approval in May 2018 based on the Phase 3 PARADIGMS trial. It works by sequestering lymphocytes in lymph nodes, preventing them from entering the central nervous system and causing inflammation. It is effective and its oral administration is an advantage for younger patients. But it carries significant safety concerns: a first-dose cardiac monitoring requirement (due to the risk of bradycardia and heart block), risk of serious infections including PML and cryptococcal meningitis, varicella zoster reactivation, and ophthalmologic monitoring requirements for macular edema. In a pediatric population, these monitoring requirements represent a real burden on families, schools, and clinical teams. Until OPERETTA 2, the absence of a high-efficacy alternative with a clinically distinct mechanism and monitoring profile left neurologists and families with limited flexibility.

How Ocrelizumab Works and Why B-Cell Depletion Matters in MS

Ocrelizumab is a humanized anti-CD20 monoclonal antibody. CD20 is a surface protein expressed on B cells throughout most of their development, from pre-B cells through mature B cells, but not on plasma cells or hematopoietic stem cells. When ocrelizumab binds CD20, it triggers B-cell depletion through three mechanisms: antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis induction.

The role of B cells in MS pathogenesis has been substantially clarified in the decade since ocrelizumab’s original approval. B cells contribute to MS inflammation not just as antibody-producing cells but as antigen-presenting cells that activate CD4+ and CD8+ T cells, as producers of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-12, and as modulators of the inflammatory microenvironment within CNS lesions. Depleting B cells interrupts these multiple contributions to disease activity, producing the robust efficacy on both relapse rates and MRI lesion accumulation that has made ocrelizumab one of the most effective MS therapies in adult practice.

In the pediatric setting, ocrelizumab’s mechanism offers specific theoretical advantages: because POMS is characterized by highly active inflammatory disease, the near-complete B-cell depletion produced by ocrelizumab (blood B-cell counts typically fall to undetectable levels within 2 weeks of the first infusion and remain suppressed for the 24-week dosing interval) may be particularly well-matched to the disease biology. The OPERETTA 2 data tests this hypothesis directly.

The OPERETTA 2 Trial: Full Results

Design

OPERETTA 2 (NCT05123703) was a randomized, double-blind, double-dummy, multicenter Phase 3 noninferiority trial. The double-dummy design means that all patients received both an IV infusion and an oral daily capsule, with one being the active drug and the other a matching placebo, ensuring neither patients nor investigators knew which treatment was assigned.

The trial enrolled 187 pediatric patients aged 10 to 17 years with RRMS, randomized 1:1 to:

Ocrelizumab 600 mg intravenous infusion every 24 weeks, plus oral placebo daily (n approximately 94)
Fingolimod 0.5 mg oral capsule daily, plus intravenous placebo infusion every 24 weeks (n approximately 93)

OPERETTA 2 was designed to demonstrate non-inferiority of ocrelizumab to fingolimod. The dose of ocrelizumab (600 mg every 24 weeks) is the same as the approved adult dose, a decision supported by pharmacokinetic and pharmacodynamic data from the companion OPERETTA 1 study that characterized ocrelizumab’s PK profile in the pediatric age range and confirmed that the adult dose produces comparable drug exposure in children aged 10 and older weighing at least 25 kg.

Primary endpoint

Outcome	Ocrelizumab	Fingolimod	Comparison
Annualized relapse rate (ARR)	Significantly reduced	Reference	Non-inferior (rate ratio 0.52; 95% CI 0.19 to 1.33)
Primary non-inferiority endpoint	Met	Reference	p-value consistent with non-inferiority

MRI endpoints (superiority)

MRI Outcome	Ocrelizumab	Fingolimod	Comparison
New or enlarging T2 hyperintense lesions per MRI scan	3.778	7.235	Relative reduction 47.8%; p=0.001
Mean T1 gadolinium-enhancing lesions at week 12	0.031	0.243	Relative reduction 87.2%; p=0.001

Source: OPERETTA 2 trial, NCT05123703. Genentech/FDA press release, May 8, 2026. Presented at AAN 2026 and published in advance of peer-reviewed journal publication.

Interpreting the results

The primary non-inferiority finding means ocrelizumab reduced annualized relapse rates in a manner that was statistically no worse than fingolimod, the current standard of care for this population. The 95% confidence interval for the rate ratio (0.19 to 1.33) is wide, reflecting the challenge of powering pediatric trials with small populations, but the point estimate (0.52) suggests that relapses were approximately 48% less frequent with ocrelizumab, a numerically superior result that did not reach formal superiority on the relapse endpoint.

The MRI superiority findings are the more clinically discriminating results. A 48% reduction in new or enlarging T2 lesions and an 87% reduction in gadolinium-enhancing lesions versus fingolimod at week 12 are substantial advantages on the imaging markers that most directly reflect ongoing inflammatory disease activity. These MRI findings align with what was observed in adult comparisons of ocrelizumab versus other MS therapies: the anti-CD20 mechanism produces particularly deep suppression of new lesion formation, which correlates with long-term disability protection in adult studies.

Safety in OPERETTA 2

The safety profile of ocrelizumab in pediatric patients in OPERETTA 2 was consistent with its well-established nine-year adult safety record. The most commonly reported adverse events were infusion reactions, infections, and decreases in immunoglobulin levels, identical in type to what is documented in adult trials.

Notably, no adverse events led to treatment withdrawal in the ocrelizumab arm during the double-blind period. This finding on discontinuation due to adverse events is clinically meaningful given that tolerability-driven discontinuation is one of the practical challenges of fingolimod’s first-dose cardiac monitoring requirement and ongoing ophthalmologic surveillance.

MSBase Registry real-world data presented at the 2026 CMSC Annual Meeting further supports the OPERETTA 2 findings: an analysis of pediatric-onset MS patients in the registry showed that ocrelizumab maintained similar effectiveness and safety in pediatric-onset disease compared to young-adult onset disease, providing external validation from clinical practice in countries where ocrelizumab has been used off-label or under compassionate access in pediatric patients.

Ocrevus’s Full Approved Indication Picture After May 2026

With the pediatric RRMS approval, Ocrevus now carries the following FDA-approved indications:

Indication	Population	Approval date
Relapsing forms of MS (CIS, RRMS, active SPMS)	Adults	March 2017
Primary progressive MS	Adults	March 2017
RRMS	Pediatric patients aged 10 years and older weighing at least 25 kg	May 8, 2026

Ocrevus also has a subcutaneous formulation, Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), approved in September 2024 for adults, which delivers the same dose subcutaneously in 10 minutes rather than the 3.5-hour intravenous infusion. The subcutaneous formulation is currently approved for adults only; the pediatric indication uses the intravenous formulation.

Safety Considerations for the Pediatric Population

The safety profile of ocrelizumab is well-established from more than nine years of adult use and now confirmed in OPERETTA 2 for the pediatric setting. Key considerations for parents and pediatric neurologists:

Infusion reactions: The most common adverse event during ocrelizumab treatment is infusion-related reactions occurring during or within 24 hours of infusion. Pre-medication with corticosteroids, antihistamines, and analgesics is administered before each infusion per protocol. These reactions are typically mild to moderate and manageable.

Infections: Because B-cell depletion reduces one component of humoral immunity, patients on ocrelizumab are at modestly increased risk of respiratory infections, particularly upper respiratory tract infections. Serious infections occurred at low rates in both adult and pediatric trials. Opportunistic infections including PML (caused by JC virus) have been reported rarely in adult patients, primarily in those with additional immunocompromising factors.

Decreasing immunoglobulins: Long-term B-cell depletion leads to gradual decline in IgG and IgM levels over years of treatment. Monitor immunoglobulin levels periodically. Significant hypogammaglobulinemia may require dose adjustment or management in some patients.

Vaccinations: Live vaccines should not be administered during treatment or until B cells have reconstituted after stopping treatment. All recommended immunizations should be completed before initiating Ocrevus. This is particularly important in the pediatric setting where routine childhood vaccination schedules need to be coordinated with treatment initiation.

PML risk: Ocrevus carries a boxed warning for progressive multifocal leukoencephalopathy (PML), though the absolute risk appears substantially lower than with natalizumab (Tysabri). No cases of PML were reported in OPERETTA 2.

Dosing and Administration for Pediatric Patients

Parameter	Details
Approved dose (ages 10 and older, weight at least 25 kg)	600 mg IV every 24 weeks
First dose	Two 300 mg infusions given 2 weeks apart
Subsequent doses	Single 600 mg infusion every 24 weeks
Pre-medication required	Methylprednisolone (or equivalent corticosteroid) IV, antihistamine, and optional antipyretic before each infusion
Infusion duration (600 mg)	Approximately 3.5 hours
Setting	Healthcare facility with emergency equipment and resuscitation capability available
Weight requirement	At least 25 kg (approximately 55 lbs)
Age lower limit	10 years and older
Not for	Children under 10 years of age or weighing less than 25 kg

What This Approval Means for Families and Pediatric Neurologists

For families of children with RRMS

For the first time, a family whose child has RRMS has a choice between two FDA-approved treatment options rather than only one. Ocrevus, administered every six months as an intravenous infusion, offers a different monitoring profile, mechanism of action, and efficacy signal than daily oral fingolimod.

Practical considerations for families when discussing this option with your child’s neurologist:

Ocrevus is infused twice a year. Fingolimod is taken daily. For some families, twice-yearly clinic visits for infusion are more manageable than ensuring daily adherence; for others, the infusion schedule is a barrier.
The first-dose cardiac monitoring requirement with fingolimod is not required with Ocrevus.
The ophthalmologic monitoring required with fingolimod is not required with Ocrevus.
The 87% reduction in gadolinium-enhancing lesions at week 12 versus fingolimod in OPERETTA 2 indicates a measurably deeper suppression of active inflammation with Ocrevus in the pediatric trial.
All immunizations should be current and any live vaccines completed before starting Ocrevus. This timing requires planning with your child’s pediatrician and neurologist.

For pediatric neurologists

OPERETTA 2 provides the first randomized head-to-head controlled evidence comparing a high-efficacy anti-CD20 therapy to fingolimod in pediatric RRMS. The non-inferiority on ARR combined with superiority on both MRI endpoints justifies positioning ocrelizumab as a strong option for treatment-naive patients with active disease, not just as a step-up therapy after fingolimod failure.

The absence of treatment withdrawal due to adverse events in the ocrelizumab arm is a meaningful tolerability signal in a population where treatment persistence over years and decades is the goal. Monitoring requirements for ocrelizumab are primarily infusion reaction surveillance, immunoglobulin levels, and standard infection monitoring, rather than the cardiac and ophthalmologic monitoring that fingolimod requires.

The American Academy of Neurology and the International Pediatric MS Study Group will be updating their guidance frameworks in response to this approval. The National MS Society’s healthcare providers section provides updated clinical resources.

For families: the National MS Society and Can Do MS both maintain dedicated pediatric MS resources. The International Pediatric MS Study Group connects families with specialized clinical expertise.

For related HED coverage of other neurological condition approvals and anti-CD20 therapy advances in 2026, see our post on Fasenra (benralizumab) approved for hypereosinophilic syndrome as another example of a biologic agent expanding from adult to pediatric and rare disease settings, and our post on VYVGART and the first approval covering all forms of myasthenia gravis.

Sources

FDA approval announcement: FDA approves ocrelizumab for relapsing-remitting multiple sclerosis in pediatric patients 10 years of age and older. FDA.gov. May 8, 2026.

Genentech press release: FDA Approves Ocrevus for Relapsing-Remitting Multiple Sclerosis in Pediatric Patients 10 Years of Age and Older. gene.com. May 8, 2026.

Drugs.com approval news: FDA Approves Ocrevus for Relapsing-Remitting Multiple Sclerosis In Pediatric Patients 10 Years of Age and Older. drugs.com. May 2026.

NeurologyLive clinical summary: FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis. neurologylive.com. May 2026.

Neurology Advisor detailed coverage: Ocrevus Approved for Pediatric Relapsing-Remitting Multiple Sclerosis. neurologyadvisor.com. May 2026.

Pharmacy Times clinical review: FDA Approves Ocrelizumab for Pediatric Relapsing-Remitting Multiple Sclerosis. pharmacytimes.com. May 2026.

Medscape coverage: FDA Approves Ocrelizumab for Pediatric Relapsing MS. medscape.com. May 2026.

MS News Today coverage: In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS. multiplesclerosisnewstoday.com. May 2026.

CMSC 2026 real-world data: CMSC 2026: Real-World Analysis Supports Ocrelizumab Use in Pediatric-Onset Multiple Sclerosis. neurologylive.com. May 2026.

Practical Neurology: FDA Approves Ocrevus for Pediatric Relapsing-Remitting MS. practicalneurology.com. May 2026.

OPERETTA 2 trial registration: NCT05123703. ClinicalTrials.gov.

Ocrevus original FDA approval: FDA approves ocrelizumab for multiple sclerosis. FDA.gov. March 2017.

Fingolimod pediatric approval: FDA approves fingolimod for pediatric patients with multiple sclerosis. FDA.gov. 2018.

Ocrevus prescribing information: OCREVUS (ocrelizumab) Prescribing Information. Genentech. 2026.

Ocrelizumab mechanism review: CD20-directed B-cell depleting therapies in MS. PMC6369883.

Pediatric MS StatPearls: Pediatric Multiple Sclerosis. StatPearls. NCBI.

Pediatric MS cognitive effects: Cognitive Impairment in Pediatric Multiple Sclerosis. PMC7897219.

ADCC mechanism: Antibody-Dependent Cell-Mediated Cytotoxicity. StatPearls. NCBI.

National MS Society pediatric resources: Pediatric MS. nationalmssociety.org.

Patient resources: National MS Society: Pediatric MS | International Pediatric MS Study Group | Can Do MS | American Academy of Neurology

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about MS treatment, including the choice of disease-modifying therapy for pediatric patients, should be made in close consultation with a pediatric neurologist or MS specialist experienced in pediatric-onset multiple sclerosis.

June 1, 2026